- Chengdu Shengnuo Biotechnology Co., Ltd. (hereinafter referred to as sinobio) was established in July 2001, located in Sichuan Dayi Economic Development Zone, with a registered capital of 60 million yuan.
- Since its establishment,Shengnuo Biotechnology has always been a “high-tech enterprise”, and its enterprise technology comes from independent research and development.
Chengdu Shengnuo Biotechnology Co., Ltd. (hereinafter referred to as sinobio) was established in July 2001, located in Sichuan Dayi Economic Development Zone, with a registered capital of 60 million yuan.
The company is a first-class domestic R & D and production enterprise of peptide drugs and amino acid drugs, which is specialized in the research and development of amino acid drugs and new dosage forms of drugs.
Mr. Wen Yongjun, the founder of Shengnuo Biotechnology, has been engaged in the research of thymopentin (and Japan) in Hainan Zhonghe for many years.
At present, he is the originator of thymosin α 1 approved for marketing in more than 30 countries around the world and the leader of the R & D and production team of stable peptide drugs.
The company pays attention to the combination of learning and research, and has formed a close strategic partnership with Sichuan University, Lanzhou University, Jilin University, Academy of Military Sciences, organic Institute of Chinese Academy of Sciences, and Provincial Institute of drug control.
It has successfully realized the industrialization transformation of multiple class I polypeptide new drugs for Chengdu Di’ao, Zhejiang Haizheng, Harbin pharmaceutical, Hainan Zhonghe, etc.
Since its establishment,Shengnuo Biotechnology has always been a “high-tech enterprise”, and its enterprise technology comes from independent research and development.
It has successively established Shengnuo Biotechnology Sichuan University peptide drug research and development joint laboratory” and “Sichuan Provincial peptide drug engineering technology research center” with Sichuan University.
Mr. Wen Yongjun, chief scientist and chairman of the company, has rich experience in peptide medicine research, and has completed the industrialization transformation of thymopentin, the first peptide drug in China, and has won the “outstanding contribution award of peptide application” in the 10th and 12th International polypeptide conferences.
Chairman Wen Yongjun is fully responsible for the technical development and operation of the company, making Shengnuo Biotechnology one of the well-known peptide R & D and production bases and a leading enterprise of polypeptide in China. With its excellent key technology of peptide synthesis and modification, Shengnuo Biotechnology has become a leader in the domestic peptide industry and has been highly praised by peers.